FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PRKAR1A-CHMP1A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PRKAR1A-CHMP1A
FusionPDB ID: 68653
FusionGDB2.0 ID: 68653
HgeneTgene
Gene symbol

PRKAR1A

CHMP1A

Gene ID

5573

5119

Gene nameprotein kinase cAMP-dependent type I regulatory subunit alphacharged multivesicular body protein 1A
SynonymsACRDYS1|ADOHR|CAR|CNC|CNC1|PKR1|PPNAD1|PRKAR1|TSE1CHMP1|PCH8|PCOLN3|PRSM1|VPS46-1|VPS46A
Cytomap

17q24.2

16q24.3

Type of geneprotein-codingprotein-coding
DescriptioncAMP-dependent protein kinase type I-alpha regulatory subunitCarney complex type 1cAMP-dependent protein kinase regulatory subunit RIalphacAMP-dependent protein kinase type I-alpha regulatory chainepididymis secretory sperm binding proteinprotein kincharged multivesicular body protein 1acharged multivesicular body protein 1/chromatin modifying protein 1chromatin modifying protein 1Aprocollagen (type III) N-endopeptidaseprotease, metallo, 1, 33kDvacuolar protein sorting-associated protein 46-1
Modification date2020032920200313
UniProtAcc

P10644

Main function of 5'-partner protein: FUNCTION: Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. {ECO:0000269|PubMed:16491121, ECO:0000269|PubMed:20215566, ECO:0000269|PubMed:26405036}.

Q9HD42

Main function of 5'-partner protein: FUNCTION: Probable peripherally associated component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in cytokinesis. Involved in recruiting VPS4A and/or VPS4B to the midbody of dividing cells. May also be involved in chromosome condensation. Targets the Polycomb group (PcG) protein BMI1/PCGF4 to regions of condensed chromatin. May play a role in stable cell cycle progression and in PcG gene silencing. {ECO:0000269|PubMed:11559747, ECO:0000269|PubMed:11559748, ECO:0000269|PubMed:19129479, ECO:0000269|PubMed:23045692}.
Ensembl transtripts involved in fusion geneENST idsENST00000358598, ENST00000392711, 
ENST00000536854, ENST00000586397, 
ENST00000588188, ENST00000589228, 
ENST00000547614, ENST00000253475, 
ENST00000397901, ENST00000535997, 
ENST00000550102, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score15 X 15 X 8=180045 X 11 X 21=10395
# samples 1848
** MAII scorelog2(18/1800*10)=-3.32192809488736
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(48/10395*10)=-4.43671154213721
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PRKAR1A [Title/Abstract] AND CHMP1A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PRKAR1A [Title/Abstract] AND CHMP1A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PRKAR1A(66511717)-CHMP1A(89713739), # samples:1
Anticipated loss of major functional domain due to fusion event.PRKAR1A-CHMP1A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAR1A-CHMP1A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAR1A-CHMP1A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAR1A-CHMP1A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAR1A-CHMP1A seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
PRKAR1A-CHMP1A seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
PRKAR1A-CHMP1A seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
PRKAR1A-CHMP1A seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgenePRKAR1A

GO:2000480

negative regulation of cAMP-dependent protein kinase activity

21812984

TgeneCHMP1A

GO:0007076

mitotic chromosome condensation

11559747

TgeneCHMP1A

GO:0016192

vesicle-mediated transport

11559748

TgeneCHMP1A

GO:0016458

gene silencing

11559747

TgeneCHMP1A

GO:0045892

negative regulation of transcription, DNA-templated

11559747



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:66511717/chr16:89713739)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PRKAR1A (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CHMP1A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000358598PRKAR1Achr1766511717+ENST00000397901CHMP1Achr1689713739-2268294117632171
ENST00000358598PRKAR1Achr1766511717+ENST00000535997CHMP1Achr1689713739-2236294117632171
ENST00000358598PRKAR1Achr1766511717+ENST00000550102CHMP1Achr1689713739-810294117632171
ENST00000392711PRKAR1Achr1766511717+ENST00000397901CHMP1Achr1689713739-2335361184699171
ENST00000392711PRKAR1Achr1766511717+ENST00000535997CHMP1Achr1689713739-2303361184699171
ENST00000392711PRKAR1Achr1766511717+ENST00000550102CHMP1Achr1689713739-877361184699171
ENST00000589228PRKAR1Achr1766511717+ENST00000397901CHMP1Achr1689713739-227930556643195
ENST00000589228PRKAR1Achr1766511717+ENST00000535997CHMP1Achr1689713739-224730556643195
ENST00000589228PRKAR1Achr1766511717+ENST00000550102CHMP1Achr1689713739-82130556643195
ENST00000536854PRKAR1Achr1766511717+ENST00000397901CHMP1Achr1689713739-2389415205753182
ENST00000536854PRKAR1Achr1766511717+ENST00000535997CHMP1Achr1689713739-2357415205753182
ENST00000536854PRKAR1Achr1766511717+ENST00000550102CHMP1Achr1689713739-931415205753182
ENST00000586397PRKAR1Achr1766511717+ENST00000397901CHMP1Achr1689713739-27307565281094188
ENST00000586397PRKAR1Achr1766511717+ENST00000535997CHMP1Achr1689713739-26987565281094188
ENST00000586397PRKAR1Achr1766511717+ENST00000550102CHMP1Achr1689713739-12727565281094188
ENST00000588188PRKAR1Achr1766511717+ENST00000397901CHMP1Achr1689713739-21511770515171
ENST00000588188PRKAR1Achr1766511717+ENST00000535997CHMP1Achr1689713739-21191770515171
ENST00000588188PRKAR1Achr1766511717+ENST00000550102CHMP1Achr1689713739-6931770515171

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000358598ENST00000397901PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0097030960.9902969
ENST00000358598ENST00000535997PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0092917650.99070823
ENST00000358598ENST00000550102PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0047471210.99525285
ENST00000392711ENST00000397901PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0108726470.98912734
ENST00000392711ENST00000535997PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0105878030.98941225
ENST00000392711ENST00000550102PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0043095740.9956904
ENST00000589228ENST00000397901PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0122335360.9877665
ENST00000589228ENST00000535997PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0117027010.9882973
ENST00000589228ENST00000550102PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0063283340.99367166
ENST00000536854ENST00000397901PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0074407480.9925593
ENST00000536854ENST00000535997PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0067185840.99328136
ENST00000536854ENST00000550102PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0071736210.99282646
ENST00000586397ENST00000397901PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0086859330.9913141
ENST00000586397ENST00000535997PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0091161360.9908839
ENST00000586397ENST00000550102PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0051359120.99486405
ENST00000588188ENST00000397901PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0140024820.98599756
ENST00000588188ENST00000535997PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0129165950.98708344
ENST00000588188ENST00000550102PRKAR1Achr1766511717+CHMP1Achr1689713739-0.0027279220.9972721

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRKAR1A-CHMP1A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PRKAR1Achr1766511717CHMP1Achr168971373917759MAFLREYFERLEKVTKNMAQVTKALD
PRKAR1Achr1766511717CHMP1Achr168971373929459MAFLREYFERLEKVTKNMAQVTKALD
PRKAR1Achr1766511717CHMP1Achr168971373930583MAFLREYFERLEKVTKNMAQVTKALD
PRKAR1Achr1766511717CHMP1Achr168971373936159MAFLREYFERLEKVTKNMAQVTKALD
PRKAR1Achr1766511717CHMP1Achr168971373941570MAFLREYFERLEKVTKNMAQVTKALD
PRKAR1Achr1766511717CHMP1Achr168971373975676MAFLREYFERLEKVTKNMAQVTKALD

Top

Potential FusionNeoAntigen Information of PRKAR1A-CHMP1A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PRKAR1A-CHMP1A_66511717_89713739.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B14:01EYFERLEKV0.95080.6695514
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B14:02EYFERLEKV0.95080.6695514
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-A02:38KVTKNMAQV0.93050.65791221
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B45:01LEKVTKNMA0.91710.90271019
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-A02:21KVTKNMAQV0.91050.80571221
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-A02:13KVTKNMAQV0.88840.65931221
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B50:02LEKVTKNMA0.83110.59951019
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-A02:20KVTKNMAQV0.8210.70041221
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B08:09EYFERLEKV0.76730.6313514
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B41:01LEKVTKNMA0.42570.94351019
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B50:01LEKVTKNMA0.11660.75041019
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B50:01REYFERLEKV0.59880.6431414
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B40:06LEKVTKNMA0.98770.63371019
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B40:06REYFERLEKV0.99880.7251414
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B73:01ERLEKVTKNMA0.99690.6304819
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-C15:02KVTKNMAQV0.99790.90971221
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-A02:03KVTKNMAQV0.93460.75071221
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-A02:14KVTKNMAQV0.91090.70151221
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-A02:06KVTKNMAQV0.91050.80571221
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-C06:17EYFERLEKV0.34410.9897514
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-C06:02EYFERLEKV0.34410.9897514
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-C07:04EYFERLEKV0.32020.9361514
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-C06:08EYFERLEKV0.24350.9884514
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-C06:06EYFERLEKV0.12870.9768514
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B50:04LEKVTKNMA0.11660.75041019
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B50:05LEKVTKNMA0.11660.75041019
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B50:04REYFERLEKV0.59880.6431414
PRKAR1A-CHMP1Achr1766511717chr1689713739294HLA-B50:05REYFERLEKV0.59880.6431414

Top

Potential FusionNeoAntigen Information of PRKAR1A-CHMP1A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PRKAR1A-CHMP1A_66511717_89713739.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-0804FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-0831FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-0831YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1104FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1106FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1117FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1117YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1135FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1138FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1143FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1144FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1146FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1147FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1150FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1150YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1152FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1152YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1154FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1156FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1156YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1158FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1160FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1172REYFERLEKVTKNMA419
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1172LREYFERLEKVTKNM318
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1177FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1178FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1183FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1183YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1184FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1188FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1188YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1189FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1311FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1342FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1405FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1405YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1408FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1408YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1411FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1411YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1415FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1418FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1418YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1423FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1423YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1443FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1443YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1445FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1445YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1456FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1456YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1459FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1459YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1480FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1491FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1491YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1496FERLEKVTKNMAQVT722
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB1-1496YFERLEKVTKNMAQV621
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB3-0201RLEKVTKNMAQVTKA924
PRKAR1A-CHMP1Achr1766511717chr1689713739294DRB3-0224RLEKVTKNMAQVTKA924

Top

Fusion breakpoint peptide structures of PRKAR1A-CHMP1A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10622YFERLEKVTKNMAQPRKAR1ACHMP1Achr1766511717chr1689713739294

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRKAR1A-CHMP1A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10622YFERLEKVTKNMAQ-7.15543-7.26883
HLA-B14:023BVN10622YFERLEKVTKNMAQ-4.77435-5.80965
HLA-B52:013W3910622YFERLEKVTKNMAQ-6.80875-6.92215
HLA-B52:013W3910622YFERLEKVTKNMAQ-4.20386-5.23916
HLA-A11:014UQ210622YFERLEKVTKNMAQ-7.5194-8.5547
HLA-A11:014UQ210622YFERLEKVTKNMAQ-6.9601-7.0735
HLA-A24:025HGA10622YFERLEKVTKNMAQ-7.52403-7.63743
HLA-A24:025HGA10622YFERLEKVTKNMAQ-5.82433-6.85963
HLA-B27:056PYJ10622YFERLEKVTKNMAQ-3.28285-4.31815
HLA-B44:053DX810622YFERLEKVTKNMAQ-5.91172-6.94702
HLA-B44:053DX810622YFERLEKVTKNMAQ-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of PRKAR1A-CHMP1A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PRKAR1A-CHMP1Achr1766511717chr16897137391019LEKVTKNMATTGGAGAAGGTGACCAAGAATATGGCC
PRKAR1A-CHMP1Achr1766511717chr16897137391221KVTKNMAQVAAGGTGACCAAGAATATGGCCCAGGTG
PRKAR1A-CHMP1Achr1766511717chr1689713739414REYFERLEKVAGGGAATACTTTGAGAGGTTGGAGAAGGTG
PRKAR1A-CHMP1Achr1766511717chr1689713739514EYFERLEKVGAATACTTTGAGAGGTTGGAGAAGGTG
PRKAR1A-CHMP1Achr1766511717chr1689713739819ERLEKVTKNMAGAGAGGTTGGAGAAGGTGACCAAGAATATGGCC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
PRKAR1A-CHMP1Achr1766511717chr1689713739318LREYFERLEKVTKNMCTCAGGGAATACTTTGAGAGGTTGGAGAAGGTGACCAAGAATATG
PRKAR1A-CHMP1Achr1766511717chr1689713739419REYFERLEKVTKNMAAGGGAATACTTTGAGAGGTTGGAGAAGGTGACCAAGAATATGGCC
PRKAR1A-CHMP1Achr1766511717chr1689713739621YFERLEKVTKNMAQVTACTTTGAGAGGTTGGAGAAGGTGACCAAGAATATGGCCCAGGTG
PRKAR1A-CHMP1Achr1766511717chr1689713739722FERLEKVTKNMAQVTTTTGAGAGGTTGGAGAAGGTGACCAAGAATATGGCCCAGGTGACC
PRKAR1A-CHMP1Achr1766511717chr1689713739924RLEKVTKNMAQVTKAAGGTTGGAGAAGGTGACCAAGAATATGGCCCAGGTGACCAAAGCC

Top

Information of the samples that have these potential fusion neoantigens of PRKAR1A-CHMP1A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LUADPRKAR1A-CHMP1Achr1766511717ENST00000358598chr1689713739ENST00000397901TCGA-44-8119-01A

Top

Potential target of CAR-T therapy development for PRKAR1A-CHMP1A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PRKAR1A-CHMP1A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PRKAR1A-CHMP1A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgenePRKAR1AC2607929Carney Complex, Type 110CLINGEN;CTD_human;GENOMICS_ENGLAND;UNIPROT
HgenePRKAR1AC3276228ACRODYSOSTOSIS 1 WITH OR WITHOUT HORMONE RESISTANCE8CTD_human;GENOMICS_ENGLAND;UNIPROT
HgenePRKAR1AC0406810Carney Complex6CLINGEN;CTD_human;GENOMICS_ENGLAND
HgenePRKAR1AC0220659Acrodysostosis4CTD_human;GENOMICS_ENGLAND;ORPHANET
HgenePRKAR1AC0010481Cushing Syndrome2CTD_human
HgenePRKAR1AC1864846PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1 (disorder)2CTD_human;GENOMICS_ENGLAND
HgenePRKAR1AC0001627Congenital adrenal hyperplasia1CTD_human
HgenePRKAR1AC0002170Alopecia1CTD_human
HgenePRKAR1AC0020456Hyperglycemia1CTD_human
HgenePRKAR1AC0021655Insulin Resistance1CTD_human
HgenePRKAR1AC0023487Acute Promyelocytic Leukemia1CTD_human;ORPHANET
HgenePRKAR1AC0026846Muscular Atrophy1CTD_human
HgenePRKAR1AC0028754Obesity1CTD_human
HgenePRKAR1AC0086873Pseudopelade1CTD_human
HgenePRKAR1AC0162311Androgenetic Alopecia1CTD_human
HgenePRKAR1AC0263477Female pattern alopecia (disorder)1CTD_human
HgenePRKAR1AC0270948Neurogenic Muscular Atrophy1CTD_human
HgenePRKAR1AC0920563Insulin Sensitivity1CTD_human
HgenePRKAR1AC1850635Atrial myxoma, familial1CTD_human;ORPHANET
HgenePRKAR1AC1854540Carney Complex, Type 21CTD_human
HgenePRKAR1AC1855520Hyperglycemia, Postprandial1CTD_human
HgenePRKAR1AC3553250ACRODYSOSTOSIS 2 WITH OR WITHOUT HORMONE RESISTANCE1CTD_human
HgenePRKAR1AC3887949Apparent mineralocorticoid excess1CTD_human
HgenePRKAR1AC4083212Alopecia, Male Pattern1CTD_human
HgenePRKAR1AC4304832Primary pigmented nodular adrenocortical disease1ORPHANET
HgenePRKAR1AC4721502Peripheral dysostosis1CTD_human